Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

Main Article Content

MG Lebwohl
J Sugarman
DM Pariser
J Bagel
T Lin
R Israel


Halobetasol, Tazarotene, Psoriasis


Abstract not available.


1. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643-659.
2. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.
3. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.